FindTrial
Sign In

[18F]FluorThanatrace

DRUG6 trials

Sponsors

Washington University School of Medicine, Abramson Cancer Center at Penn Medicine

Conditions

Breast CancerCancerNeuroendocrine Carcinoma MetastaticPancreatic TumorsProstate CancerProstate Cancer MetastaticSuspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Early Phase 1

PET Imaging of PARP Activity in Cancer
NCT02469129
Washington University School of MedicineCancer
Start: 2015-03-31End: 2025-07-31Target: 50Updated: 2023-12-12
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
Active, not recruitingNCT03334500
Abramson Cancer Center at Penn MedicineProstate Cancer
Start: 2017-07-14End: 2027-02-11Target: 30Updated: 2026-02-20

Phase 1

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Active, not recruitingNCT02637934
Abramson Cancer Center at Penn MedicineSuspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Start: 2016-01-14End: 2028-08-01Updated: 2026-09-02
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer
Active, not recruitingNCT03083288
Abramson Cancer Center at Penn MedicineBreast Cancer
Start: 2017-02-22End: 2027-07-01Target: 30Updated: 2026-07-13
FTT PET/CT in Pancreatic Neuroendocrine Tumors
RecruitingNCT07114939
Abramson Cancer Center at Penn MedicineNeuroendocrine Carcinoma Metastatic, Pancreatic Tumors
Start: 2025-10-01End: 2027-09-01Target: 12Updated: 2026-02-02

Unknown Phase

FTT PET/CT in Metastatic Prostate Cancer
RecruitingNCT05242744
Abramson Cancer Center at Penn MedicineProstate Cancer Metastatic
Start: 2023-03-01End: 2027-07-01Target: 30Updated: 2026-06-26

Related Papers

Abstract P2-07-04: [18F]FluorThanatrace PET imaging correlates with response to PARP inhibitors in breast cancer: a pilot study
Clinical Cancer Research2025-06-13
Abstract PS05-02: PET Imaging of PARP Expression as a Biomarker of Response to Chemotherapy in Breast Cancer: A Nonrandomized Clinical Trial
Cancer Research2024-05-02
18F-FluorThanatrace (18F-FTT) positron emission tomography (PET/CT) in prostate cancer measures in vivo PARP-1 expression and is associated with adverse clinicopathologic features.
Journal of Clinical Oncology2022-06-013 citations
In vivo visualization of PARP inhibitor pharmacodynamics
JCI Insight2021-04-2131 citations
A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.
2018-04-16110 citations